Genomic Alterations as Potential Therapeutic Targets in Extramammary Paget’s Disease of the Vulva

Abstract

EMPD of the vulva has a chronic and relapsing course, often requiring multiple surgical resections. Effective topical treatments are lacking. We identified targetable mutations (<i>PIK3CA</i> or <i>ERBB2</i>) in > 25% of a real-world clinical cohort. Additional prospective research implementing targetable therapies for EMPD treatment is warranted.